|
Press
Releases
Press
Release: Tuesday May 8th, 2001
TheraLife® Inc. presents unique
Drug Delivery Enhancement System at "Innovative Drug Development"
conference.
New York, May 8th, 2001 - TheraLife® Inc.
today announced that Dr. Lily Yang, CEO and President of
TheraLife® Inc., has been selected to present
at the "Innovative Drug Development 2001" Conference at
the Plaza Hotel, New York City on May 7-8, 2001.
TheraLife® is a botanical drug company with
a drug enhancement technology platform - TheraLife®
Enhancer. This technology is a multi-component system that
combines the benefits of faster, safer delivery with reduced
side effects. Dr. Yang will discuss the scientific basis
for the technology's ability to enhance drug delivery through
increased intracellular metabolism, microcirculation and
the protection of liver and kidney.
Dr. Yang will summarize results from several clinical studies,
including a Stage I clinical trial study using TheraLife®
Eye plus Enhancer for the treatment of dry eyes, allergy
and eye fatigue. "The eye normally has poor circulation
and is difficult for oral medication to reach", Dr. Yang
says. This Stage I clinical results further verify the merits
of the TheraLife® Enhancer. Other clinical
studies for the treatment of wrist strain indicates that
the TheraLife® Wrist plus Enhancer relieved
pain 75% faster.
The TheraLife® Enhancer technology can be
used with a wide variety of ethical drugs, biopharmaceuticals,
botanical drugs and nutraceuticals. TheraLife®
has already developed 5 tissue specific formulas with market
potential of $50 billion for treating medical conditions
of the eye, wrist, neck and shoulder, back, and mental fatigue.
TheraLife® is in the process of extending
this technology platform to cancer, cardiovascular, metabolic,
autoimmune, and infectious diseases.
TheraLife®'s corporate strategy is directed
at forming joint ventures, marketing and distribution, product
development, and licensing partnerships with major industry
players. As such, TheraLife® is focused on
building a strong basis for attracting corporate partnerships
through strong professional advocacy, clinical data and
publications, quality manufacturing, process control and
effective marketing communications.
Notice: This release and oral statements made from time
to time by TheraLife® representatives concerning
the same subject matter may contain so-called "forward-looking
statements." These statements can be identified by introductory
words such as "expects", "plans", "will", "estimates", "forecasts",
"projects", or words of similar meaning, and by the fact
that they do not relate strictly to historical or current
facts. Forward-looking statements frequently are used in
discussing regulatory submissions and approvals, development
programs, etc. Many factors may cause actual results to
differ from forward-looking statements, including inaccurate
assumptions and a broad variety of risks and uncertainties,
some of which are known and other of which are not. No forward-looking
statement is a guarantee of future results or events, and
one should avoid paying undue reliance on such statements.
COMPANY CONTACT:
James Alston
E-mail: Jalston@theralife.com
(650) 917-1989
(650) 917-1434 fax
101 First Street
Los Altos, CA 94022
www.theralife.com
|
